This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AngioDyanamics (ANGO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) fiscal third-quarter results benefit from strong growth across all businesses and higher revenues.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako, broad product portfolio and solid international growth. However, pricing pressure raises concern.
Merit Medical WRAPSODY Gets 2 FDA Breakthrough Device Nods
by Zacks Equity Research
This regulatory clearance is expected to bolster Merit Medical Systems' (MMSI) cardiovascular segment.
Here's Why You Should Hold on to Avanos Medical Stock Now
by Zacks Equity Research
Avanos Medical (AVNS) continues to benefit from strong performing segments and robust product portfolio. However, weak performance at Acute Pain unit raises concern.
Here's Why You Should Add Integer Holdings to Your Portfolio
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from solid presence in the broader MedTech space and portfolio management.
Merit Medical (MMSI) Down 24.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to benefit from growing product pipeline, strong R&D focus and strategic acquisitions.
PDCO or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. MMSI: Which Stock Is the Better Value Option?
Merit Medical (MMSI) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Merit Medical's (MMSI) fourth-quarter results gain from higher revenues and solid segmental performance benefit. However, contraction in gross margin remains a concern.
Merit Medical (MMSI) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 17.65% and 2.24%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical (MMSI) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Merit Medical's (MMSI) Q3 earnings gain from higher revenues and solid segmental performance benefit. However, contraction in gross margin remains a concern.
Merit Medical (MMSI) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of -37.78% and -1.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Merit Medical (MMSI) Q3 Earnings Expected to Decline
by Zacks Equity Research
Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merit Medical (MMSI) Down 37.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merit Medical (MMSI) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.
Merit Medical (MMSI) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of -16.00% and -1.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical (MMSI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Pharmacy International Hit Walgreens (WBA) Q3 Earnings?
by Zacks Equity Research
Challenging market conditions, especially in retail, causes a slowdown in the Retail Pharmacy International division at Walgreens Boots (WBA).
HSIC vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. MMSI: Which Stock Is the Better Value Option?
Merit Medical Acquires Brightwater Medical for $35 Million
by Zacks Equity Research
The Brightwater Medical-acquisition broadens Merit Medical's (MMSI) product offerings.
Merit Medical Systems Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Merit Medical Systems has been struggling lately, but the selling pressure may be coming to an end soon.
Here's Why You Should Bet on Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to benefit from solid product pipeline, HeRO product line and persistent focus on R&D.
Merit Medical (MMSI) Down 4.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Here is Why Growth Investors Should Buy Merit Medical (MMSI) Now
by Zacks Equity Research
Merit Medical (MMSI) is well positioned to outperform the market, as it exhibits above-average growth in financials.